



# Stabilis



## Amphotericin B



Noms commerciaux

Amfotericina B	Argentine, Brésil, Equateur, Espagne
Amphotericin B	Autriche, Emirats Arabes Unis, Etats Unis d'Amérique
Amphotericina B	Chili, Colombie, Pérou
Amphotericine B	Hongrie
Fungizona	Espagne
Fungizone	Allemagne, Australie, Belgique, Canada, Colombie, Danemark, Finlande, France, Grande Bretagne, Grèce, Hongrie, Inde, Iran, Irlande, Italie, Luxembourg, Malaisie, Maroc, Norvège, Nouvelle Zélande, Pays bas, Pérou, Portugal, Suède, Suisse, Tunisie, Turquie, Vénézuéla
Terix	Mexique



### Stabilité des solutions

PVC	◆	0,05 & 0,5 mg/ml	23°C-25°C	☀ ±	24	✓		12
PVC	◆	0,1 mg/ml	15°C-25°C	☀ /	24	✓		435
PVC	◆	0,1 mg/ml	4°C	☀ /	15	◐		1907
PVC	◆	0,1 & 0,25 mg/ml	4°C	☀ /	35	◐		436
PVC	◆	0,2 & 0,5 mg/ml	25°C	☀	120	✓		283
PVC	◆	0,2 & 0,5 & 1 mg/ml	4°C	☀ /	120	✓		283
PVC	◆ 10	0,1 mg/ml	15°C-25°C	☀ /	24	✓		435
PVC	◆ 15	0,1 mg/ml	15°C-25°C	☀ /	24	✓		435
PVC	◆ 20	0,1 mg/ml	15°C-25°C	☀ /	24	✓		435
POF	◆	0,47 >> 0,75 mg/ml	25°C	☀	24	✓		497
POF	◆	0,92 >> 1,4 mg/ml	25°C	?	36	✓		439
POF	◆	0,92 >> 1,4 mg/ml	6°C	☀ /	36	✓		439
PI	◆	0,2 & 0,5 mg/ml	4°C	☀ /	10	◐		604



## Facteur influençant la stabilité

					892
					1172 3591
	RL				1172 3968
					265 270 793 984 1498 2043
					301
					3591
	[ 0.05 mg/ml				3869






































































## Compatibilités

		Amphotericin B : 0.6 mg/ml Amifostine : 10 mg/ml		3
		Amphotericin B	RL	3968
		Amphotericin B Amikacin sulfate		3549
		Amphotericin B : 0,5 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Amphotericin B : 0.6 mg/ml Amsacrine : 1 mg/ml		253
		Amphotericin B : 0,6 mg/ml Anidulafungin : 0,5 mg/ml		1982
		Amphotericin B : 0.6 mg/ml Aztreonam : 40 mg/ml		99
		Amphotericin B : 0.6 mg/ml Bivalirudin : 5 mg/ml		1713
		Amphotericin B Bivalirudin		3539
		Amphotericin B : 0.6 mg/ml		265
		Amphotericin B : 1.6 mg/ml Aldesleukin : 0.0338 MUI/ml		36
		Amphotericin B : 0.6 mg/ml Allopurinol sodium : 3 mg/ml	 	307
		Amphotericin B Calcium gluconate		3644
		Amphotericin B : 0.1 mg/ml	RL	1172

		Amphotericin B Cefotaxime sodium		3871
		Amphotericin B : 0.1 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Amphotericin B		270
		Amphotericin B : 0,6 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Amphotericin B : 1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Amphotericin B : 0.1 mg/ml Cefpirome sulfate : 50 mg/ml	RL	280
		Amphotericin B : 0.1 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Amphotericin B : 0,6 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Amphotericin B : 0,6 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Amphotericin B Ceftazidime		3883
		Amphotericin B Ceftobiprole medocartil sodium		4650
		Amphotericin B : 0.6 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml		2269
		Amphotericin B : 0.6 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml	RL	2269
		Amphotericin B : 0.1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Amphotericin B : 0.1 mg/ml Cimetidine hydrochloride : 0.6 mg/ml		1201
		Amphotericin B : 0.1 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Amphotericin B : 0.6 mg/ml Cisatracurium besylate : 2 & 5 mg/ml		299
		Amphotericin B : 0.6 mg/ml Cisatracurium besylate : 0.1 mg/ml		299
		Amphotericin B : 0.6 mg/ml Docetaxel : 0.9 mg/ml		1754
		Amphotericin B : 0.6 mg/ml		1415
		Amphotericin B Dopamine hydrochloride		3638
		Amphotericin B : 0.6 mg/ml		301
		Amphotericin B : 0.1 mg/ml Diltiazem hydrochloride : 1 mg/ml		198
		Amphotericin B		3591
		Amphotericin B : 0.6 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Amphotericin B : 0,6 mg/ml Doripenem : 5 mg/ml		2262
		Amphotericin B : 0.6 mg/ml Famotidine : 2 mg/ml		215

		Amphotericin B : 0.1 mg/ml Fluconazole : 2 mg/ml		256
		Amphotericin B : 0.09 mg/ml		984
		Amphotericin B : 0.6 mg/ml Doripenem : 5 mg/ml		2262
		Amphotericin B : 0.6 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Amphotericin B : 0.1 mg/ml Enalaprilate : 0.0125 mg/ml		1703
		Amphotericin B : 0.1 mg/ml Enalaprilate : 1.25 mg/ml		201
		Amphotericin B : 0.6 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Amphotericin B : 0.6 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Amphotericin B : 0.6 mg/ml Filgrastim : 30 µg/ml		244
		Amphotericin B : 5 mg/ml Fluconazole : 2 mg/ml		496
		Amphotericin B : 5 mg/ml Foscarnet sodium : 24 mg/ml		73
		Amphotericin B Foscarnet sodium		3662
		Amphotericin B : 0.6 mg/ml Foscarnet sodium : 24 mg/ml		1135
		Amphotericin B : 1.35 mg/ml		793
		Amphotericin B : 0.6 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Amphotericin B : 0.01 >> 5 mg/ml		1498
		Amphotericin B : 0.1 mg/ml Fosfomycin : 30 mg/ml		4055
		Amphotericin B : 0.6 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Amphotericin B : 0,6 & 1,2 mg/ml		2043
		Amphotericin B : 0.6 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Amphotericin B : 0.6 mg/ml Hetastarch : 60 mg/ml		1721
		Amphotericin B : 0.1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Amphotericin B : 0.6 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Amphotericin B Linezolid		3560
		Amphotericin B : 0.6 mg/ml Linezolid : 2 mg/ml		1925
		Amphotericin B : 0,04 & 0,08 mg/ml Magnesium sulfate : 2 & 4 mg/ml		682
		Amphotericin B : 0.6 mg/ml Melphalan : 0.1 mg/ml		169

		Amphotericin B : 0.6 mg/ml Melphalan : 0.1 mg/ml		169
		Amphotericin B : 0.2 mg/ml Meropenem : 1 & 20 mg/ml		266
		Amphotericin B : 5 mg/ml Meropenem : 1 & 50 mg/ml		266
		Amphotericin B N-acetylcysteine : 200 mg/ml		3766
		Amphotericin B : 4 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Amphotericin B : 0.6 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Amphotericin B : 0.1 mg/ml Oritavancin : 0.8>>2 mg/ml		3152
		Amphotericin B : 0.6 mg/ml Paclitaxel : 1.2 mg/ml		248
		Amphotericin B Pantoprazole sodium		2090
		Amphotericin B : 0.6 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Amphotericin B Penicillin G sodium		3585
		Amphotericin B : 0,1 mg/ml Pentoxifyllin : 5 mg/ml		4543
		Amphotericin B : 1 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Amphotericin B : 0.6 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Amphotericin B : 0,1 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Amphotericin B : 0.6 mg/ml Propofol : 10 mg/ml		300
		Amphotericin B : 0.6 mg/ml Remifentanil hydrochloride : 25 µg/ml		59
		Amphotericin B : 0.6 mg/ml Remifentanil hydrochloride : 250 µg/ml		59
		Amphotericin B Rocuronium bromide		3564
		Amphotericin B : 50 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Amphotericin B : 0.6 mg/ml Sargramostim : 10 µg/ml		335
		Amphotericin B : 0.6 mg/ml Sargramostim : 10 µg/ml		335
		Amphotericin B : 5 mg/ml Tacrolimus : 1000 µg/ml		479
		Amphotericin B : 0,1 mg/ml Telavancin hydrochloride : 7,5 mg/ml		3254
		Amphotericin B : 0.1 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Amphotericin B : 0.6 mg/ml Vinorelbine tartrate : 1 mg/ml		84

		Amphotericin B : 0.1 mg/ml		1172
		Amphotericin B		3591
		Amphotericin B : 0.1 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Amphotericin B : ? mg/ml		892
		Amphotericin B : 0.6 mg/ml Teniposide : 0.1 mg/ml		905
		Amphotericin B Thiopental sodium : 25 mg/ml		3767
		Amphotericin B : 0.6 mg/ml Thiotepa : 1 mg/ml		249
		Amphotericin B Tigecycline		3332
		Amphotericin B : 0.6 mg/ml Zidovudine : 4 mg/ml		337



## Voie d'administration



## Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
12	Revue	Owens LC, Fleming RA, Restino MS, Cruz JM, Hurd DD. Stability of amphotericin B 0.05 and 0.5 mg/ml in 20% fat emulsion. Am J Health-Syst Pharm 1997 ; 54: 683-686.
36	Revue	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.



99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
201	Revue	Thompson DF, Allen LV, Stiles ML. Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2530-2531.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
256	Revue	Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208.
265	Revue	Trissel LA. Amphotericin B does not mix with fat emulsion. Am J Health-Syst Pharm 1995 ; 52: 1463-1464.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
270	Revue	Heide PE. Precipitation of amphotericin B from IV fat emulsion. Am J Health-Syst Pharm 1997 ; 54: 1449.
280	Revue	Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433.

283	Revue	Lee MD, Hess MM, Boucher BA, Apple AM. Stability of amphotericin B in 5% dextrose injection stored at 4 or 25°C for 120 hours. Am J Hosp Pharm 1994 ; 51: 394-396.
285	Revue	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
435	Revue	Wiest DB, Maish WA, Garner SS, El-Chaar GM. Stability of amphotericin B in four concentrations of dextrose injection. Am J Hosp Pharm 1991 ; 48: 2430-2433.
436	Revue	Mitrano FP, Outman WR, Baptista RJ, Palombo JD. Chemical and visual stability of amphotericin B in 5% dextrose injection stored at 4°C for 35 days. Am J Hosp Pharm 1991 ; 48: 2635-2637.
439	Revue	Kintzel PE, Kennedy PE. Stability of amphotericin B in 5% dextrose injection at concentrations used for administration through a central venous line. Am J Hosp Pharm 1991 ; 48: 283-285.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
497	Revue	Kintzel PE, Kennedy PE. Stability of amphotericin B in 5% dextrose injection at 25°C. Am J Hosp Pharm 1991 ; 48: 1681.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998



682	Revue	Raymond GG, Davis RL. Physical compatibility and chemical stability of amphotericin B in combination with magnesium sulfate in 5% dextrose injection. Ann Pharmacotherapy 1991 ; 25: 123-126.
793	Revue	Ranch?re JY, Latour JF, Fuhrmann C, Lagallarde C, Loreuil F. Amphotericin B intralipid formulation: stability and particule size. J Antimicrob Chemother 1996 ; 37: 1165-1169.
892	Revue	Kintzel PE, Smith GH. Practical guidelines for preparing and administering amphotericin B. Am J Hosp Pharm 1992 ; 49: 1156-1164.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
984	Revue	Ericsson O, Hallmen AC, Wikstrom I. Amphotericin B is incompatible with lipid emulsions. Ann Pharmacotherapy 1996 ; 30: 298.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1172	Revue	Jurgens RW, DeLuca PP, Papadimitriou D. Compatibility of amphotericin B with certain large-volume parenterals. Am J Hosp Pharm 1981 ; 38: 377-378.
1201	Revue	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Balduin JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1498	Revue	Cleary JD. Amphotericin B formulated in a lipid emulsion. Ann Pharmacotherapy 1996 ; 30: 409-412.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1703	Revue	Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.

1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1907	Revue	Burger DE, Caldwell JW. Sustaining treatment of coccidioidal meningitidis by extending the stability of amphotericin B. Hosp Pharm 2004 ; 39: 554-557.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2043	Revue	Walker S, Tailor SAA, Lee M, Louie L, Louie M, Simor AE. Amphotericin B in lipid emulsion : stability, compatibility, and in vitro antifungal activity. Antimicrob Agents Chemother 1998 ; 42: 762-766.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.


3332	Laboratoire	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3539	Laboratoire	Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3560	Laboratoire	Linezolid (Zyvox®) - Summary of Product Characteristics Pharmacia 2013
3564	Laboratoire	Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012
3585	Laboratoire	Benzylnicillin sodium - Summary of Product Characteristics Genus Pharmaceuticals 2008
3591	Laboratoire	Amphotericine B (Fungizone®) - Résumé des caractéristiques du produit Bristol Myers Squibb 2011
3638	Laboratoire	Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics Hospira 2010
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3662	Laboratoire	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhi R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidone/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3869	Revue	Sun P, Chen J, Zhang Z, Gao X, Chen P, Li X. Influence of 5% dextrose volume on amphotericin B deoxycholate preparation J Pharm Pharmacol 2016 ; 68: 433-438.
3871	Poster	Soussi M.A, Soualah-alila R, jenene F, Lazreg O, Razgallah Khrouf M. Peut-on administrer le céfotaxime en Y avec d'autres médicaments injectables ? Synpreph Congress Clermont Ferrand, France 2016
3883	Laboratoire	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3968	Laboratoire	Ringer lactate - Résumé des Caractéristiques du Produit Fresenius Kabi 2015
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44

4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4543	Revue	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021

# Stabilis



## Amphotericin B



### Stabilité des préparations

		3700 mg Fungizone®	NaHCO3 1.4% >> 500 ml	19-23°C		3		2820
		3700 mg Fungizone®	NaHCO3 1.4% >> 500 ml	19-23°C		3		2820
		3700 mg Fungizone®	NaHCO3 1.4% >> 500 ml	4°C		15		2820




### Bibliographie

	Type	Source
2820	Revue	Groeschke J, Solassol I, Bressolle F, Pinguet F. Stability of amphotericin B and nystatin in antifungal mouthrinses containing sodium hydrogen carbonate J Pharm Biomed Anal 2006 ; 42: 362-366.

# Stabilis



## Amphotericin B



### Stabilité des préparations

	50 mg Fungizone® NaHCO <sub>3</sub> 4,2% 0,1 mL Glucose 5% >> 10 mL	-20°C		60			3848
	15 mg Fungizone® Glucose 5% >> 3 ml	2-6°C		120			2867
	15 mg Fungizone® Glucose 5% >> 3 ml	20-25°C		16			2867
	15 mg Fungizone® Glucose 5% >> 3 ml	20-25°C		13			2867
	10 mg Fungizone® Glucose 5% 4 mL	23-27°C		28			4487
	10 mg Fungizone® Glucose 5% 4 mL	3-7°C		168			4487



### Facteur influençant la stabilité

	25°C			2867
--	------	--	--	------



### Bibliographie

	Type	Source
2867	Revue	Peyron F, Elias R, Ibrahim E, Amirat-Combralier V, Bu?s-Charbit M, Balansard G. Stability of Amphotericin B in 5% Dextrose Ophthalmic Solution. Int J Pharm Compound 1999 ; 3, 4: 316-320.
3848	Thèse	Dermu Marine. Etude de stabilité d&#39;un collyre à l&#39;amphotéricine B 0,5%. Thèse de doctorat en pharmacie 2014




4487	Revue	Chennell P, Yessaad M, Abd El Kader F, Jouannet M, Wasiak M, Bouattour Y, Sautou V. Do Ophthalmic Solutions of Amphotericin B Solubilised in 2-Hydroxypropyl- $\beta$ -Cyclodextrins Possess an Extended Physicochemical Stability? Pharmaceutics 2020 ; 12, 786.
------	-------	---

# Stabilis



## Amphotericin B



### Stabilité des préparations

ng Fungizona® (Squibb Industria Farmaceutica)		Eau ppi >> 50 ml	20-25°C		30			3069
ng Fungizona® (Squibb Industria Farmaceutica)		Eau ppi >> 50 ml	4-8°C		30			3069



### Bibliographie

	Type	Source
3069	Revue	Juarez JC, Lopez RM, Hucto M et al. Stability of amphotericin B in water solution for inhalation. Eur Hosp Pharm 1997 ; 3: 59-60.



# Dictionnaire

	Antifongique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Polyvinyl chlorure
	Glucose 5%		Avec ou sans lumière
	Heure		A l'abri de la lumière
	Jour		Lumière
	Glucose 10%		Glucose 15%
	Glucose 20%		Polyolefine
	Non précisée		Elastomère en polyisoprène
	Facteur influençant la stabilité		Solvant
	Chlorure de sodium 0,9%		Provoque
	Précipitation		Dégradation
RL	Ringer lactate		Nutrition parentérale (mélange ternaire)
	Nutrition parentérale (mélange binaire)		NaCl 0,9% + bactériostatique
	Compatibilités		Molécule
	Turbidité immédiate		Incompatible
	Incompatibilité non précisée		Compatible
	Précipitation immédiate		Instabilité de l'émulsion immédiate
	Perte de turbidité		NaCl 0,9% ou glucose 5%
	Précipitation en 1 heure		Instabilité chimique
	Chlorure de sodium 0,45%		Aucun
	Turbidité en 2 heures		Turbidité en 4 heures
	Turbidité en 1 heure		Précipitation en 4 heures
	Solvant spécifique		Précipitation en 2 heures
	Eau pour préparation injectable		Précipitation en 8 heures
	Voie d'administration		Perfusion intraveineuse

 Intrathécale	 Intravésicale
 Intrapleurale	 Intrapéritonéale
 Intravitréenne	 Intraarticulaire
 Sous conjonctivale	 Bibliographie
 Gargarisme	 Stabilité des préparations
 Origine	 Excipient
 Verre	 Poudre
 Polypropylène	 Collyre
 Flacon injectable	 Flacon plastique
 Diminution de la stabilité	 Aérosol
 Dictionnaire	